GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen Read more
Vect-Horus Enters Exclusive License Agreement with Novo Nordisk to Develop Targeted Therapeutics Read more
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) Read more
ViiV Healthcare receives approval from China’s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine), the first and only complete long-acting HIV-1 injectable treatment Read more
New data for Arexvy, GSK’s RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease Read more
Servier Announces FDA Approval of TIBSOVO (ivosidenib tablets) for the Treatment of IDH1-Mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS) Read more
Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer Read more